01—Abstract
Summary
Summary of the 10-K filed February 24, 2020. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. reported a net loss of $72.2 milliona for 2019 on total revenues of $196.0 million, compared with a net loss of $80.3 million on $151.9 million of revenue in 2018.
The year was dominated by the November 4, 2019 announcement that the HALO-301 Phase 3 study of PEGPH20 failed to reach its primary overall survival endpoint (11.2 vs. 11.5 median months). The company halted PEGPH20 development, closed its oncology operations and cut headcount by approximately 55%, or about 160 positions, to focus solely on its ENHANZE technology and Hylenex. It recorded $28.4 millionb of restructuring charges in the fourth quarter of 2019 and expects to become sustainably profitable beginning in the second quarter of 2020.
Revenue mix shifted considerably. Revenues under collaborative agreements were $60.0 millionc, including $45.0 million from the argenx collaboration, and product sales, net, rose to $66.0 million from $28.2 million, driven mainly by bulk rHuPH20 sales to Janssen. Royalties declined to $69.9 million from $79.0 million.
Customer concentration was high: Roche accounted for 40% of 2019 total revenues, argenx 23% and Janssen 18%. The balance sheet changed significantly. In November 2019 the company issued $460.0 milliond of 1.25% Convertible Senior Notes due 2024 and used $200.0 million of the net proceeds to repurchase shares, alongside a $550.0 million three-year capital return program.
Cash, cash equivalents and marketable securities were $421.3 million at year-end, and management believes these resources will fund operations for at least the next twelve months. Stockholders' equity fell to $91.8 million from $248.9 million, and the Royalty-backed Loan is estimated to be repaid in the second quarter of 2020.
02—Key points
Key Highlights
- Net loss of $72.2 million in 2019, improved from a net loss of $80.3 million in 2018; total revenues rose to $196.0 million from $151.9 million.
- HALO-301 Phase 3 study of PEGPH20 failed its primary overall survival endpoint; development halted, oncology operations closed, and headcount reduced by approximately 55% (about 160 positions).
- Restructuring and one-time charges of $28.4 million recorded in Q4 2019, with the company anticipating sustainable profitability beginning in Q2 2020.
- Product sales, net increased to $66.0 million from $28.2 million, mainly from bulk rHuPH20 sales to Janssen; royalties declined to $69.9 million from $79.0 million.
- Issued $460.0 million of 1.25% Convertible Senior Notes due 2024 and repurchased $200.0 million of common stock; a $550.0 million three-year capital return program was authorized.
- Customer concentration is high: Roche (40%), argenx (23%) and Janssen (18%) of 2019 total revenues.
- Cash, cash equivalents and marketable securities of $421.3 million at December 31, 2019; stockholders' equity declined to $91.8 million from $248.9 million.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2019, Halozyme Therapeutics lost $0.37.
- Revenue$196.0M100.0%
- Cost of revenue−$45.5M23.2%
- Gross profit$150.4M76.8%
- Operating costs−$218.1M111.3%
- Operating income−$67.6M34.5%
- Interest, other & tax−$4.6M2.4%
- Net income−$72.2M36.9%
04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 24, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $195.99M$151.86M | +29.1% |
| Cost of Revenue | $45.55M$10.14M | +349.3% |
| Gross Profit | $150.45M$141.73M | +6.2% |
| R&D Expenses | $140.80M$150.25M | −6.3% |
| SG&A Expenses | $77.25M$60.80M | +27.1% |
| Operating Expenses | $263.60M$221.19M | +19.2% |
| Operating Income | -$67.61M-$69.33M | +2.5% |
| Interest Expense | $11.63M$18.04M | −35.6% |
| Net Income | -$72.24M-$80.33M | +10.1% |
| EPS (Basic) | $-0.50$-0.56 | +10.7% |
| EPS (Diluted) | $-0.50$-0.56 | +10.7% |
| Shares Outstanding (Basic) | 144.33M143.60M | +0.5% |
| Shares Outstanding (Diluted) | 144.33M143.60M | +0.5% |
05—Questions
Frequently Asked Questions
Why did Halozyme restructure and cut about 55% of its workforce?
Following the November 4, 2019 failure of the HALO-301 Phase 3 study of PEGPH20 to reach its primary overall survival endpoint, the company halted PEGPH20 development, closed its oncology operations and implemented a restructuring to focus solely on ENHANZE and Hylenex. The restructuring reduced headcount by approximately 55%, or about 160 positions.
How much debt does Halozyme carry and when does it come due?
Total consolidated indebtedness, net of debt discount, was $402.6 million at December 31, 2019. This includes $460.0 million aggregate principal of 1.25% Convertible Senior Notes due 2024 and a $19.5 million net balance on the Royalty-backed Loan, which the company estimates will be repaid in the second quarter of 2020. The Oxford and SVB loan was repaid in November 2019 with $26.1 million.
What is the outlook for profitability and liquidity?
The company expects to achieve sustainable profitability beginning in the second quarter of 2020 after completing the restructuring and recording related one-time charges. Management believes current cash, cash equivalents and marketable securities of $421.3 million will be sufficient to fund operations for at least the next twelve months, supplemented by anticipated collaboration revenues and possible future financings.
How concentrated is Halozyme's revenue among its partners?
Revenue is concentrated among a few collaborators. In 2019, Roche accounted for 40% of total revenues, argenx 23% and Janssen 18%, down from Roche's 72% in 2018. Royalties and collaboration revenues depend on partners' ability to develop and commercialize products such as Herceptin SC and DARZALEX SC.
06—Continue